OTC PEDIATRIC DOSING FOR COUGH/COLD COMBINATION PRODUCTS
This article was originally published in The Tan Sheet
Executive Summary
OTC PEDIATRIC DOSING FOR COUGH/COLD COMBINATION PRODUCTS is still being considered as a topic for a future Nonprescription Drugs Advisory Committee meeting, OTC Monograph Review Staff Director William Gilbertson, PharmD, told industry representatives at a July 12 "OTC feedback" meeting. Indicating that cough/cold combination products may be the focus of the pediatric labeling discussion, Gilbertson said FDA is considering "taking this issue for resolution to the nonprescription drags advisory panel... because [the cough/cold combination final monograph] is a very complex document."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning